KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Free Cash Flow (2019 - 2025)

GoodRx Holdings' Free Cash Flow history spans 7 years, with the latest figure at $85.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 466.22% year-over-year to $85.3 million; the TTM value through Dec 2025 reached $164.4 million, up 43.21%, while the annual FY2025 figure was $164.4 million, 43.21% up from the prior year.
  • Free Cash Flow for Q4 2025 was $85.3 million at GoodRx Holdings, up from $59.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $123.0 million in Q3 2024 and bottomed at -$27.1 million in Q2 2024.
  • The 5-year median for Free Cash Flow is $29.1 million (2021), against an average of $33.3 million.
  • The largest annual shift saw Free Cash Flow tumbled 278.04% in 2024 before it skyrocketed 466.22% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $23.7 million in 2021, then surged by 170.26% to $64.0 million in 2022, then crashed by 75.21% to $15.9 million in 2023, then crashed by 246.75% to -$23.3 million in 2024, then surged by 466.22% to $85.3 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Free Cash Flow are $85.3 million (Q4 2025), $59.8 million (Q3 2025), and $10.1 million (Q2 2025).